Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437073 · ClinicalTrials.gov registry record · Phase 2
Brain Metastases In ErbB2-Positive Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00437073 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 22 participants.
The verdict
NCT00437073, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. The study will determine how safe and effective lapatinib is when given in combination with capecitabine to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed regularly during the course of the study.
Interventions
- DRUG capecitabine
- DRUG topotecan
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437073
The ClinicalTrials.gov registry entry for NCT00437073 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which capecitabine is the first listed.
NCT00437073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437073 about?
NCT00437073 is a clinical study titled "Brain Metastases In ErbB2-Positive Breast Cancer". This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. The study will determine how safe and effective lapatin...
What is the current status of trial NCT00437073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00437073?
The interventions under investigation include: capecitabine (DRUG), topotecan (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00437073?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.